InMed Pharmaceuticals (INM) Amortization of Deferred Charges (2022 - 2026)
InMed Pharmaceuticals' (INM) quarterly Amortization of Deferred Charges came in at $82949.0 in Q1 2026, up 7.34% year-on-year from $77278.0 in Q1 2025, and down 20.86% quarter-over-quarter from $104818.0 in Q4 2025.
InMed Pharmaceuticals (INM) Amortization of Deferred Charges (2022 - 2026) Analysis & Trends
InMed Pharmaceuticals' Amortization of Deferred Charges history runs 5 years deep, the most recent figure standing at $82949.0 for Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 7.34% year-over-year to $82949.0 in Q1 2026; TTM through Mar 2026 was $369575.0, a 8.49% increase from a year earlier, with the FY2025 full-year figure at $321885.0, down 16.38% from the prior year.
- Amortization of Deferred Charges retreated to $82949.0 in Q1 2026 per INM's latest filing, from $104818.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $104818.0 in Q4 2025 and bottomed at $75876.0 in Q4 2024.
- The 5-year median for Amortization of Deferred Charges is $93085.0 (2023), against an average of $91516.6.
- Biggest YoY gain for Amortization of Deferred Charges was 38.14% in 2025; the steepest drop was 19.33% in 2025.
- Year by year, Amortization of Deferred Charges stood at $90389.0 in 2022, then increased by 2.98% to $93085.0 in 2023, then declined by 18.49% to $75876.0 in 2024, then jumped by 38.14% to $104818.0 in 2025, then fell by 20.86% to $82949.0 in 2026.
- Per Business Quant, the three latest INM Amortization of Deferred Charges figures stand at $82949.0 (Q1 2026), $104818.0 (Q4 2025), and $103478.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.85 Bn | 32.11 Bn | 1.97 Bn |
| 3 | Zoetis | 32.48 Bn | 30.54 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - |
| 7 | Viatris | 20.33 Bn | 18.53 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.43 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn |
| 10 | InMed Pharmaceuticals | 6.92 Mn | 1.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 82,949.00 |
| Mar 31, 2026 | 82,949.00 |
| Dec 31, 2025 | 104,818.00 |
| Dec 31, 2025 | 104,818.00 |
| Sep 30, 2025 | 103,478.00 |
| Sep 30, 2025 | 103,478.00 |
| Jun 30, 2025 | 78,330.00 |
| Jun 30, 2025 | 78,330.00 |
| Mar 31, 2025 | 77,278.00 |
| Mar 31, 2025 | 77,278.00 |
| Dec 31, 2024 | 75,876.00 |
| Dec 31, 2024 | 75,876.00 |
| Sep 30, 2024 | 90,401.00 |
| Sep 30, 2024 | 90,401.00 |
| Jun 30, 2024 | 97,094.00 |
| Jun 30, 2024 | 97,094.00 |
| Mar 31, 2024 | 95,615.00 |
| Mar 31, 2024 | 95,615.00 |
| Dec 31, 2023 | 93,085.00 |
| Dec 31, 2023 | 93,085.00 |